TY - JOUR
T1 - Hematologic toxicities associated with intravenous immunoglobulin therapy
AU - Baxley, Allison
AU - Akhtari, Mojtaba
PY - 2011/11
Y1 - 2011/11
N2 - Intravenous immunoglobulin (IVIG) is an immunomodulating agent that induces beneficial therapeutic responses in children and adults. IVIG is not only used for prophylaxis and therapy of infections in patients with primary and secondary immunodeficiencies associated with defective antibody production, but also used for treatment of patients with systemic inflammatory disorders, autoimmune diseases, and neuroimmunologic conditions. IVIG is generally considered a safe and efficacious therapeutic modality. However, it is associated with certain adverse effects including hematologic complications such as hemolytic anemia, leukopenia, neutropenia, monocytopenia, disseminated intravascular coagulation, and changes in blood rheology. Venous and arterial thrombotic complications can also occur following treatment with IVIG in high risk patients. It is very important for clinicians to have the knowledge of those adverse events profiles; and this article summarizes hematologic toxicities associated with IVIG therapy reported in the literature; and describes strategies for their identification and management.
AB - Intravenous immunoglobulin (IVIG) is an immunomodulating agent that induces beneficial therapeutic responses in children and adults. IVIG is not only used for prophylaxis and therapy of infections in patients with primary and secondary immunodeficiencies associated with defective antibody production, but also used for treatment of patients with systemic inflammatory disorders, autoimmune diseases, and neuroimmunologic conditions. IVIG is generally considered a safe and efficacious therapeutic modality. However, it is associated with certain adverse effects including hematologic complications such as hemolytic anemia, leukopenia, neutropenia, monocytopenia, disseminated intravascular coagulation, and changes in blood rheology. Venous and arterial thrombotic complications can also occur following treatment with IVIG in high risk patients. It is very important for clinicians to have the knowledge of those adverse events profiles; and this article summarizes hematologic toxicities associated with IVIG therapy reported in the literature; and describes strategies for their identification and management.
KW - Adverse effects
KW - Hematologic
KW - IVIG
KW - Toxicities
UR - http://www.scopus.com/inward/record.url?scp=84860419082&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84860419082&partnerID=8YFLogxK
U2 - 10.1016/j.intimp.2011.07.024
DO - 10.1016/j.intimp.2011.07.024
M3 - Review article
C2 - 21843660
AN - SCOPUS:84860419082
SN - 1567-5769
VL - 11
SP - 1663
EP - 1667
JO - International Immunopharmacology
JF - International Immunopharmacology
IS - 11
ER -